Novartis launches interactive Retina App

Article

Novartis has launched a fully interactive Facebook app, ?Retina App,? which simulates retinal disease by illustrating the user?s journey with a highly realistic view of the possible impact of vision loss on their daily lives.

Basel, Switzerland-To raise awareness of retinal disease, Novartis has launched a fully interactive Facebook app, “Retina App” on World Sight Day October 10, 2013. The app, part of the “Set Your Sights” campaign, simulates retinal disease by illustrating the user’s journey with a highly realistic view of the possible impact of vision loss on their daily lives.

The app is geared to encourage patients with retinal diseases, such as wet age-related macular degeneration, diabetic macular edema, retinal vein occlusion, and choroidal neovascularization secondary to pathologic myopia, to engage with vision loss and experience what it means to live with a sight-diminishing condition. Users of the app will be presented with a fully tailored, through-the-lens view of their own photos and friends video experience that is a highly realistic view of what their life with retinal disease could be like.

The “Set Your Sights” campaign was mounted in response to the “2020 Vision Report” from the World Health Organization that concluded that nearly 80% of global blindness is preventable if managed correctly.

“As the global leader in the field of retinal disease, Novartis is proud to support World Sight Day by creating further dialogue among people living with low-vision conditions and the wider community, generating an environment of understanding and tolerance,” said David Epstein, head of the pharmaceuticals division, Novartis Pharma AG. “This is an important initiative in the pharmaceutical environment, reflecting our focus to always put the patient first.”

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Christine Curcio, PhD, of the University of Alabama at Birmingham Heersink School of Medicine, shares histology update and revised nomenclature for OCT with Sheryl Stevenson of the Eye Care Network and Ophthalmology Times
SriniVas R. Sadda, MD, FARVO, shares key points from his retina presentation at the International SPECTRALIS Symposium
Robert Sergott, MD, describes fluorescence lifetime imaging ophthalmoscopy (FLIO) and the International SPECTRALIS Symposium – And Beyond (ISS) in Heidelberg, Germany.
Rayaz Malik, MBChB, PhD, a professor of medicine at Weill Cornell Medicine - Qatar, spoke with Ophthalmology Times Europe about his presentation. It's titled "An eye on neurodegenerative diseases: Challenging the dogma" at the International SPECTRALIS Sympsoium. In conversation with Hattie Hayes, Ophthalmology Times Europe
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
© 2025 MJH Life Sciences

All rights reserved.